Trial Profile

First-in-human Phase 1 single ascending dose study assessing ART2612

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ART 2612 (Primary)
Indications Chemotherapy-induced damage; Peripheral neuropathies
Focus Adverse reactions; First in man

Most Recent Events

02 Jun 2025 According to Artelo Biosciences media release, company expects to report results from a food effect study with ART26.12 this summer.
28 Apr 2025 Status changed from recruiting to active, no longer recruiting.
31 Mar 2025 According to Artelo Biosciences media release, A Phase 1 Single Ascending Dose study in healthy volunteers with ART26.12, Artelo's lead FABP5 inhibitor, is nearing completion with data expected in Q2 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com